Gilead Sciences (GILD) – Investment Analysts’ Weekly Ratings Updates

Posted by Matthew Steigler on Dec 25th, 2024

Gilead Sciences logo Several analysts have recently updated their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

12/11/2024 – Gilead Sciences had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $84.00 price target on the stock.
12/11/2024 – Gilead Sciences had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $80.00 price target on the stock.
12/10/2024 – Gilead Sciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $105.00 to $115.00. They now have an “outperform” rating on the stock.
12/10/2024 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Bank of America Co.. They now have a $109.00 price target on the stock.
11/21/2024 – Gilead Sciences had its price target raised by analysts at Mizuho from $90.00 to $100.00. They now have an “outperform” rating on the stock.
11/21/2024 – Gilead Sciences had its price target raised by analysts at UBS Group AG from $70.00 to $96.00. They now have a “neutral” rating on the stock.
11/18/2024 – Gilead Sciences had its price target raised by analysts at Royal Bank of Canada from $81.00 to $84.00. They now have a “sector perform” rating on the stock.
11/18/2024 – Gilead Sciences was upgraded by analysts at Daiwa America to a “hold” rating.
11/15/2024 – Gilead Sciences is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $110.00 price target on the stock.
11/14/2024 – Gilead Sciences is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $125.00 price target on the stock.
11/13/2024 – Gilead Sciences was upgraded by analysts at Citigroup Inc. to a “strong-buy” rating.
11/8/2024 – Gilead Sciences had its price target raised by analysts at Truist Financial Co. from $83.00 to $97.00. They now have a “hold” rating on the stock.
11/8/2024 – Gilead Sciences was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating.
11/7/2024 – Gilead Sciences had its price target raised by analysts at Royal Bank of Canada from $75.00 to $81.00. They now have a “sector perform” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $105.00. They now have an “overweight” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $100.00 to $105.00. They now have an “overweight” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at Piper Sandler from $95.00 to $105.00. They now have an “overweight” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $95.00 to $105.00. They now have an “outperform” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at BMO Capital Markets from $94.00 to $102.00. They now have an “outperform” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at Robert W. Baird from $80.00 to $95.00. They now have a “neutral” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $74.00 to $84.00. They now have a “neutral” rating on the stock.
11/7/2024 – Gilead Sciences had its price target raised by analysts at Cantor Fitzgerald from $70.00 to $80.00. They now have a “neutral” rating on the stock.
11/7/2024 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
11/7/2024 – Gilead Sciences had its price target raised by analysts at Barclays PLC from $84.00 to $95.00. They now have an “equal weight” rating on the stock.
10/29/2024 – Gilead Sciences had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $75.00 price target on the stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $93.95 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The firm’s fifty day simple moving average is $90.97 and its two-hundred day simple moving average is $81.06. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $117.09 billion, a P/E ratio of 1,043.89, a P/E/G ratio of 2.38 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. During the same quarter in the previous year, the firm posted $2.29 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.28%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares in the company, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 1.96 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 455,734 shares of company stock valued at $42,069,746. 0.29% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Gilead Sciences by 350.1% in the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after buying an additional 1,793,145 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after buying an additional 1,622,806 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its position in Gilead Sciences by 24.7% during the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after acquiring an additional 1,564,792 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.